Asymmetrical dimethylarginine - more sensitive than NT-proBNP to diagnose heart failure in adults with congenital heart disease

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Tutarel, Oktay ^a   Denecke, Agnieszka ^a   Bode Böger, Stefanie M ^b   Martens Lobenhoffer, Jens ^b   Lovric, Svjetlana ^a   Bauersachs, Johann ^a   Schieffer, Bernhard ^a   Westhoff Bleck, Mechthild ^a   Kielstein, Jan T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; N(G),N(G) DIMETHYLARGININE; ARGININE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIMETHYLARGININE; DRUG DERIVATIVE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CARDIOPULMONARY FUNCTION; CONGENITAL HEART DISEASE; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; BLOOD; CONGENITAL HEART MALFORMATION; ECHOCARDIOGRAPHY; EXERCISE TEST; HEART LEFT VENTRICLE FUNCTION; MORTALITY;

ADULT; ARGININE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEART DEFECTS, CONGENITAL; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; ROC CURVE; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 84858652161     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033795     Document Type: Article

References (29)

1. Shaddy RE, Webb G, (2008) Applying heart failure guidelines to adult congenital heart disease patients. Expert Rev Cardiovasc Ther 6: 165-174.
2. Diller GP, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, et al. (2005) Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 112: 828-835.
3. Norozi K, Wessel A, Buchhorn R, Alpers V, Arnhold JO, et al. (2007) Is the Ability index superior to the NYHA classification for assessing heart failure?: comparison of two classification scales in adolescents and adults with operated congenital heart defects. Clin Res Cardiol 96: 542-547.
4. Larsson DA, Meurling CJ, Holmqvist F, Waktare JE, Thilen UJ, (2007) The diagnostic and prognostic value of brain natriuretic peptides in adults with a systemic morphologically right ventricle or Fontan-type circulation. Int J Cardiol 114: 345-351.
5. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, et al. (2002) Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106: 92-99.
6. Bolger AP, Coats AJ, Gatzoulis MA, (2003) Congenital heart disease: the original heart failure syndrome. Eur Heart J 24: 970-976.
7. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-2442.
8. Giannakoulas G, Dimopoulos K, Bolger AP, Tay EL, Inuzuka R, et al. (2010) Usefulness of natriuretic Peptide levels to predict mortality in adults with congenital heart disease. Am J Cardiol 105: 869-873.
9. Garg R, Raman SV, Hoffman TM, Hayes J, Daniels CJ, (2008) Serum markers of systemic right ventricular function and exercise performance. Pediatr Cardiol 29: 641-648.
10. Feng Q, Lu X, Fortin AJ, Pettersson A, Hedner T, et al. (1998) Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res 37: 667-675.
11. Kielstein JT, Bode-Boger SM, Klein G, Graf S, Haller H, et al. (2003) Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest 33: 370-375.
12. Visser M, Paulus WJ, Vermeulen MA, Richir MC, Davids M, et al. (2010) The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. Eur J Heart Fail 12: 1274-1281.
13. von Haehling S, Bode-Boger SM, Martens-Lobenhoffer J, Rauchhaus M, Schefold JC, et al. (2010) Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol. Clin Pharmacol Ther 88: 506-512.
14. Wilson Tang WH, Tong W, Shrestha K, Wang Z, Levison BS, et al. (2008) Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J 29: 2506-2513.
15. Warnes CA, Liberthson R, Danielson GK, Dore A, Harris L, et al. (2001) Task force 1: the changing profile of congenital heart disease in adult life. J Am Coll Cardiol 37: 1170-1175.
16. Martens-Lobenhoffer J, Bode-Boger SM, (2006) Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 52: 488-493.
17. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, et al. (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16: 777-802.
18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612.
19. Dimopoulos K, Okonko DO, Diller GP, Broberg CS, Salukhe TV, et al. (2006) Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. Circulation 113: 2796-2802.
20. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, et al. (1998) Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62: 2425-2430.
21. Kielstein JT, Fliser D, Veldink H, (2009) Asymmetric dimethylarginine and symmetric dimethylarginine: axis of evil or useful alliance? Semin Dial 22: 346-350.
22. Sibal L, Agarwal SC, Home PD, Boger RH, (2010) The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev 6: 82-90.
23. Massion PB, Feron O, Dessy C, Balligand JL, (2003) Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 93: 388-398.
24. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, et al. (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109: 172-177.
25. Thum T, Tsikas D, Stein S, Schultheiss M, Eigenthaler M, et al. (2005) Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 46: 1693-1701.
26. Zoccali C, (2003) ADMA: a critical cardio-renal link in heart failure? Eur J Clin Invest 33: 361-362.
27. Oechslin E, Kiowski W, Schindler R, Bernheim A, Julius B, et al. (2005) Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation 112: 1106-1112.
28. Kim HN, Januzzi JL Jr, (2011) Natriuretic peptide testing in heart failure. Circulation 123: 2015-2019.
29. Gewillig M, Brown SC, Eyskens B, Heying R, Ganame J, et al. (2010) The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg 10: 428-433.